Diamyd Medical has strengthened its production capabilities through an expanded strategic alliance with APL and a new collaboration with NorthX Biologics. The partnership brings together complementary expertise in active substance production, fill and finish, and validation, centered around Diamyd Medical’s manufacturing site in Umeå. The initiative aims to support the transition from clinical development to commercial manufacturing while reinforcing northern Sweden as a hub for life science and advanced biologics production.

Read the article here